Nrf2 deficiency increases oligodendrocyte loss, demyelination, neuroinflammation and axonal damage in an MS animal model.
Animals
Axons
/ drug effects
Cuprizone
/ toxicity
Demyelinating Diseases
/ chemically induced
Disease Models, Animal
Inflammation
/ chemically induced
Mice
Mice, Knockout
Multiple Sclerosis
/ chemically induced
NF-E2-Related Factor 2
/ deficiency
Oligodendroglia
/ metabolism
Oxidative Stress
/ drug effects
Cuprizone model
Demyelination
Multiple sclerosis
Nrf2
Oligodendrocyte loss
Oxidative stress
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
21
03
2019
accepted:
27
08
2019
pubmed:
19
9
2019
medline:
30
1
2021
entrez:
19
9
2019
Statut:
ppublish
Résumé
Oxidative stress is a pathophysiological hallmark of many CNS diseases, among multiple sclerosis (MS). Accordingly, boosting the astrocytic transcription factor nuclear factor E2-related factor 2 (Nrf2) system in an MS mouse model efficiently ameliorates oligodendrocyte loss, neuroinflammation and axonal damage. Moreover, Dimethylfumarate, an efficient activator of Nrf2, has recently been approved as therapeutic option in MS treatment. Here, we use the cuprizone mouse model of MS to induce oxidative stress, selective oligodendrocyte loss, microglia and astrocyte activation as well as axonal damage in both wild type and Nrf2-deficient mice. We found increased oligodendrocyte apoptosis and loss, pronounced neuroinflammation and higher levels of axonal damage in cuprizone-fed Nrf2-deficient animals when compared to wild type controls. In addition, Nrf2-deficient animals showed a higher susceptibility towards cuprizone within the commissura anterior white matter tract, a structure that is relatively insensitive to cuprizone in wild type animals. Our data highlight the cuprizone model as a suitable tool to study the complex interplay of oxidative stress, neuroinflammation and axonal damage. Further studies will have to show whether distinct expression patterns of Nrf2 are involved in the variable susceptibility towards cuprizone in the mouse.
Identifiants
pubmed: 31529356
doi: 10.1007/s11011-019-00488-z
pii: 10.1007/s11011-019-00488-z
doi:
Substances chimiques
NF-E2-Related Factor 2
0
Nfe2l2 protein, mouse
0
Cuprizone
5N16U7E0AO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-362Références
Acta Neurol Belg. 2020 Aug;120(4):853-861
pubmed: 30182258
Mol Cell Biol. 2004 Dec;24(24):10941-53
pubmed: 15572695
Drug Metab Rev. 2006;38(4):769-89
pubmed: 17145701
FASEB J. 2005 Jul;19(9):1061-6
pubmed: 15985529
J Mol Neurosci. 2018 Oct;66(2):229-237
pubmed: 30140996
Experientia. 1982 Jul 15;38(7):784-5
pubmed: 6286340
Ther Adv Neurol Disord. 2015 Jan;8(1):20-30
pubmed: 25584071
Redox Biol. 2017 Aug;12:843-853
pubmed: 28448946
J Mol Neurosci. 2019 Feb;67(2):265-275
pubmed: 30547416
Neuroscience. 2018 Sep 15;388:69-86
pubmed: 30025861
Mol Neurobiol. 2019 Feb;56(2):1109-1123
pubmed: 29873041
J Neuroimmunol. 2018 Aug 15;321:61-65
pubmed: 29957389
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13943-8
pubmed: 8943040
Glia. 2019 Feb;67(2):263-276
pubmed: 30511355
Anat Cell Biol. 2018 Jun;51(2):119-127
pubmed: 29984057
Acta Neuropathol Commun. 2017 Dec 01;5(1):94
pubmed: 29195512
Front Cell Neurosci. 2018 Apr 27;12:114
pubmed: 29755324
Antioxid Redox Signal. 2010 Nov 1;13(9):1375-84
pubmed: 20367259
J Neurochem. 1996 Sep;67(3):1014-22
pubmed: 8752107
Mol Neurobiol. 2019 Jun;56(6):3984-3998
pubmed: 30238390
Mol Cell Proteomics. 2019 Mar;18(3):504-519
pubmed: 30587509
J Neurochem. 2018 Feb;144(3):285-301
pubmed: 29210072
J Neurol Sci. 2008 Nov 15;274(1-2):48-53
pubmed: 18684473
Front Neurosci. 2019 Feb 11;13:86
pubmed: 30804745
Brain Pathol. 2001 Jan;11(1):107-16
pubmed: 11145196
Clin Sci (Lond). 2015 Dec;129(12):989-99
pubmed: 26386022
Biochemistry. 2017 Mar 14;56(10):1518-1528
pubmed: 28186720
Physiol Rev. 2014 Jul;94(3):909-50
pubmed: 24987008
Brain. 2008 Jul;131(Pt 7):1722-35
pubmed: 18515320
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Mol Pharmacol. 2008 Jun;73(6):1785-95
pubmed: 18334601
J Invest Dermatol. 2007 Apr;127(4):835-45
pubmed: 17235328
Biomed Rep. 2016 May;4(5):519-522
pubmed: 27123241
Iran J Basic Med Sci. 2017 Aug;20(8):886-893
pubmed: 29085580
Free Radic Biol Med. 2015 Nov;88(Pt B):101-107
pubmed: 26057936
J Mol Neurosci. 2017 Apr;61(4):617-624
pubmed: 28238065
Neurosci Biobehav Rev. 1997 Mar;21(2):151-66
pubmed: 9062938
Glia. 2016 Dec;64(12):2219-2230
pubmed: 27641725
J Neurosci Res. 2004 Aug 15;77(4):540-51
pubmed: 15264224
Redox Biol. 2015 Dec;6:472-485
pubmed: 26432659
Glia. 2012 Oct;60(10):1468-80
pubmed: 22689449
Front Neuroanat. 2015 Jul 08;9:91
pubmed: 26217195
PLoS One. 2010 Jul 23;5(7):e11769
pubmed: 20668697
Histochem Cell Biol. 2013 Aug;140(2):105-17
pubmed: 23744526
Acta Neuropathol. 2010 Jan;119(1):37-53
pubmed: 19847447
J Neurosci. 2016 Jan 27;36(4):1410-5
pubmed: 26818526
Antioxidants (Basel). 2016 Sep 07;5(3):
pubmed: 27618111
Clin Exp Immunol. 2006 Jul;145(1):101-7
pubmed: 16792679
Metab Brain Dis. 2016 Apr;31(2):425-33
pubmed: 26725831